Skip Navigation

A Phase III, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator?s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor ARPI, in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC - rechARge

Brief Summary

Type:
Prostate

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06764485

Study #:
STUDY00161316

Start Date:
May 21, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06764485

View Complete Trial Details & Eligibility at ClinicalTrials.gov